<DOC>
	<DOCNO>NCT00555542</DOCNO>
	<brief_summary>To study effect T cell peripheral blood patient RA undergo selective B cell depletion study . We analyze B T cell subset patient active RA treat undergoing form treatment rituximab .</brief_summary>
	<brief_title>An Analysis Peripheral Blood T Cell Subsets Rheumatoid Arthritis</brief_title>
	<detailed_description>- In open label prospective study , evaluate therapeutic efficacy peripheral blood cellular response rituximab 10 patient active RA despite conventional DMARDs therapy . - Patients take stable dose methotrexate least 10mg folic acid per week least 4 week . Rituximab administrate 1000mg intravenous infusion day 1 day 15 . Premedication standard prescription consist methylprednisolone 100mg IV , Chlorpheniramine maleate ( piriton 10mg IV oral paracetamol 500mg give 30 minute infusion rituximab . Oral prednisolone 60mg tob e give day 1-6 rituximab infusion 30mg day 7-13 . - In patient relapse follow first cycle repeat second cycle must fulfill follow condition : 1 . Patients must respond clinically first infusion improvement 2 . Other disease modify anti-rheumatic drug ( DMARDs ) appropriate determine investigator , either ineffective due side effect , 3 . Patients disease activity score DSA &gt; 2.6 4 . At least 24 week since first infusion 5 . Neutrophil count &gt; 1.5 X 103/mcL - The second infusion consist rituximab 1000mg intravenous infusion day 1 day 15 protocol follow every 4 week 52 week day first infusion.14 Premedication standard prescription ( consist methylprednisolone 100mg IV , Chlorpheniramine maleate ( piriton ) 10mg IV oral paracetamol 500mg give 30 minute infusion rituximab .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age 21 Fulfilled 1978 American college Rheumatology ( ACR ) criteria RA Seropositive RF RF &gt; 20 IU/ml Active disease despite treatment least 2 stable dose DMARDs least 16 week , include MRX &gt; 10mg weekly 4 swollen and/or tender joint Stable dose prednisolone &lt; =12.5mg/day NASID lease 4 week MTX &gt; 10mg/wk folic acid &gt; 10 mg/wk lease 4 week Little ability selfcare Used DMARD MTX ( Leflunomide washout cholestyramine 4 week prior screen ) Received intraarticular , intramuscular , intravenous corticosteroid last 4 week Concurrent treatment biologics within 8 week Infected joint prosthesis previous 5 year Autoimmune disease RA ( except concurrent Sjogren 's syndrome ) , active rheumatoid vasculitis , history systemic disease associate arthritis , chronic fatigue syndrome . Serious infection , hepatitis , pneumonia , pyelonephritis previous 3 month Any chronic infectious disease renal infection , chest infection bronchiectasis sinusitis Recurrent bacterial infection encapsulate organism , primary secondary immunodeficiency Active tuberculosis require treatment within previous 3 year Opportunistic infection herpes zoster within previous 2 month Any evidence active cytomegalovirus ; active Pneumocystis Jirovecl ; drugresistant atypical mycobacterial infection Known hypersensitivity murine proteins Current sign symptom severe , progressive , uncontrolled renal , hepatic , haematological , gastrointestinal , endocrine , pulmonary , cardias , neurological , cerebral disease A history lymphoproliferative disease include lymphoma sign suggestive disease , lymphadenopathy unusual size location ( ie , lymphadenopathy node , posterior tangle neck , infraclavicular epitrochlear , periaortic area ) ; splenomegaly Any know malignant disease except basal cell carcinoma currently last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>B-cell</keyword>
	<keyword>rituximab</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>